-
Mashup Score: 12024 Cancer Survivorship Walkathon - 22 day(s) ago
Dawood Findakly’s Fundraising Page.
Source: www.pledgereg.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Virtual Mentoring Program - 24 day(s) ago
ASCO’s Virtual Mentoring Program pairs members with a mentor outside of their institution to address unmet career development needs of practicing oncologists, populations underrepresented in
Source: society.asco.orgCategories: General Medicine News, Hem/OncsTweet-
RT @ASCOTECAG: Virtual Mentoring Program – applications open in the fall. https://t.co/2e1EvT31pQ Become a Topical Mentor at the ASCO Annu…
-
-
Mashup Score: 7Combined Hematology/Oncology and Hospice & Palliative Medicine - 1 month(s) ago
This program targets trainees wanting to further their palliative care skills to be able to deliver high-quality cancer care with palliative/supportive care integrated across the continuum of care.
Source: society.asco.orgCategories: General Medicine News, Hem/OncsTweet-
📢 Exciting Opportunity! 🎓 Join us for an info session on an ACGME-approved pilot for Combined Heme/Onc and Hospice & Palliative Medicine Training! 🌟 Website: https://t.co/wrYkmyvOxF 🌟 4/8/24 from 7:00 – 8:00 pm ET 🌟 Zoom: https://t.co/S6tuvl4lMr https://t.co/vjWHlbjuZZ
-
-
Mashup Score: 67Precision treatment in advanced hepatocellular carcinoma - 2 month(s) ago
The past decade has witnessed significant advances in the systemic treatment of advanced hepatocellular carcinoma (HCC). Nevertheless, the newly devel…
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet-
RT @ArndtVogel: Precision treatment in advanced hepatocellular carcinoma @Cancer_Cell https://t.co/O3GzKgUo17 👏Excellent review on precisi…
-
-
Mashup Score: 67Precision treatment in advanced hepatocellular carcinoma - 2 month(s) ago
The past decade has witnessed significant advances in the systemic treatment of advanced hepatocellular carcinoma (HCC). Nevertheless, the newly devel…
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet-
RT @ArndtVogel: Precision treatment in advanced hepatocellular carcinoma @Cancer_Cell https://t.co/O3GzKgUo17 👏Excellent review on precisi…
-
-
Mashup Score: 1Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities - 3 month(s) ago
Falchi and colleagues review the development of and clinical experience with bispecific antibodies, a class of T-cell redirecting drugs with excellent activity
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities. #lymsm @ASH_hematology #MedTwitter #OncTwitter https://t.co/X4Hc7ror0l
-
-
Mashup Score: 18
Original Article from The New England Journal of Medicine — Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
Source: www.nejm.orgCategories: Expert Picks, Latest HeadlinesTweet-
RT @ramsedhom: We forget median OS for EGFR mutated lung cancer is ~3 years, >40% with grade III adverse events https://t.co/ridfj3r8VB I…
-
-
Mashup Score: 38myelocast - 7 month(s) ago
A new Flutter project.
Source: eatoure.github.ioCategories: Expert Picks, Latest HeadlinesTweet-
RT @VincentRK: https://t.co/pb66TroSSj Introducing a one-stop site to estimate risk of progression in myeloma, SMM, MGUS. Bookmark it! #Me…
-
-
Mashup Score: 6FDA Approves Momelotinib for Myelofibrosis With Anemia - 7 month(s) ago
The FDA has approved momelotinib (Ojjaara) for the treatment of adult patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis, and anemia.
Source: www.onclive.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @OncLive: BREAKING: @US_FDA Approves Momelotinib for Myelofibrosis With Anemia https://t.co/v06kpcjene https://t.co/gYqNlug1tg
-
-
Mashup Score: 21
Background: The treatment of follicular lymphoma (FL) has previously centered on chemoimmunotherapy, which can be disadvantageous due to patient intolerance, cumulative toxicities, and disease refractoriness. Targeted therapies can produce deep responses and improve progression-free and overall survival with more tolerable adverse event profiles. Methods: We summarize the current literature and key clinical trials regarding targeted therapies in follicular lymphoma both in the front-line and in the relapsed-refractory setting. Results: Targeted therapies studied in FL include immune modulators, anti-CD20 antibodies, Bruton’s tyrosine kinase (BTK) inhibitors, enhancers of zeste homolog 2 (EZH2) inhibitors, phosphoinositide 3-kinase (PI3K) inhibitors, and B-cell lymphoma 2 (BCL-2) inhibitors. Chimeric antigen receptor (CAR-T) therapy and bispecific T-cell engager (BiTE) therapies also show promise in monotherapy and in combination with targeted therapies. These therapies exhibit high ove
Source: www.mdpi.comCategories: Expert Picks, Latest HeadlinesTweet-
RT @smbenlazar: Targeted Therapy in Follicular Lymphoma: Towards a Chemotherapy-Free Approach https://t.co/cbzm2d9YoO #mdpicancers via @Can…
-
🎗️ Join me in supporting #CancerSurvivorship through the Wellness & Integrative Medicine Program at Ochsner #LSU Health Shreveport – Feist-Weiller #Cancer Center! Every #donation counts! Click the link to contribute: https://t.co/mTWcmk3Q7T #Fundraiser @LSUHS #MedTwitter https://t.co/9TdQD6KibY